WWW.EXFILE.COM, INC. -- 13637 -- BOSTON SCIENTIFIC CORP. -- FORM 8-K

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 21, 2005

BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)

DELAWARE
1-11083
04-2695240
(State or other
(Commission
(IRS employer
jurisdiction of
file number)
identification no.)
incorporation)
    

One Boston Scientific Place, Natick, Massachusetts
01760-1537
(Address of principal executive offices)
(Zip code)

Registrant’s telephone number, including area code:  (508) 650-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the fling obligation of the registrant under any of the following provisions:

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 
 
 

Item 8.01.    Other Events.

On June 21, 2005, a jury in Delaware found that Boston Scientific's TAXUS® Express™, Express™, Express™ Biliary, and Liberté™ stents infringe a Johnson & Johnson patent, and that the Liberté stent infringes a second J&J patent. This suit was originally filed by J&J (through its subsidiary Cordis Corporation) on January 13, 2003 in the U.S. District Court for the District of Delaware. The jury only determined liability; monetary damages will be determined in a later trial. Boston Scientific intends to appeal the decision. A copy of the press release issued by the Company is attached as Exhibit 99.1 to this Report.


Item 9.01.    Financial Statements and Exhibits.

99.1    Press Release dated June 21, 2005



 
 
 


SIGNATURE


Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  BOSTON SCIENTIFIC CORPORATION
 
 		  
 		  
 
Date: June 24, 2005 By:   /s/ Lawrence J. Knopf
 
Lawrence J. Knopf
  Vice President and Assistant General Counsel 

 



 
 
 

INDEX TO EXHIBITS

 
Exhibit   
Number  Description 
   
99.1  Press Release dated June 21, 2005